Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Webcasts|October 22, 2020
Particles, Powders and Pills – Optimized Raman across the Formulation Spectrum
Author(s)Renishaw
***Live:Friday, November 13, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET *** From contaminants in injectables to the fate of APIs in nasal sprays, Raman reveals the identity and distribution of materials in complex formulations. In this webinar we describe the best approaches to characterizing common pharmaceutical samples; from morphologically targeted analysis of filtered particles to full three-dimensional chemical imaging of whole tablets.*** On demand available after final airing until Nov. 13, 2021.***
Register free:
Event Overview: This webcast will present methodologies to characterize a range of pharmaceutical materials from contaminant particles through to powders and pressed tablets. Each method requires an approach to ensure nothing is missed but analysis is rapid and complete. From selective pinpoint analysis based on particle morphology, to complete chemical images, the discussion will demonstrate how to optimize Raman data collection and analysis for the sample of interest.
Four cases will be covered
- Microparticles on a filter
- Deposits from nasal sprays
- Mixed powders
- Pressed tablets
Key Learning Objectives:
- How to speed analysis of large complex samples without data loss
- How to best analyze filtered particles
- The importance of magnification and focus to the analytical result
- Obtaining quantitative and qualitative data from images
- Understand the role of Raman spectroscopy in characterizing pharmaceutical products from dispersed particles through to whole tablets
Speakers: Tim Smith, Head of Applications, Renishaw Spectroscopy
Sarah Shidler, Ph.D, Applications Scientist,, Reinshaw Spectroscopy
Time and Date: Friday, November 13, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET
On demand available after final airing until Nov. 13, 2021
Sponsor: Renishaw
Register free:
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5